The Filing Desk

Recursion Pharmaceuticals vs Vir Biotechnology

Recursion Pharmaceuticals RXRX · Vir Biotechnology VIR · Biotechnology

Recursion Pharmaceuticals reported revenue of $75 million in fiscal 2025, about the same as Vir Biotechnology's $69 million in fiscal 2025. Recursion Pharmaceuticals' revenue grew 26.9% in its latest year, and Vir Biotechnology's fell 7.6%. Recursion Pharmaceuticals had an operating margin of -867.9%, against -699.2% at Vir Biotechnology. Free cash flow was −$378 million at Recursion Pharmaceuticals and −$397 million at Vir Biotechnology.

Side by side

Recursion PharmaceuticalsVir Biotechnology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$75M$69M
Revenue growth26.9%−7.6%
Revenue growth a year, last 5 years79.6%−2.1%
Gross margin5.0%100.0%
Operating margin−867.9%−699.2%
Net margin−863.4%−638.9%
Free cash flow−$378M−$397M
Free cash flow margin−506.5%−578.5%
Return on capital−117.2%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count63.2%1.7%
Last close$3.19$9.96
P/E at the last close——
Insider trades, last 12 monthssold $7.1 millionsold $8.2 million
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Recursion PharmaceuticalsVir Biotechnology
Operating margin
Percent of revenue
Recursion PharmaceuticalsVir Biotechnology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Recursion PharmaceuticalsVir Biotechnology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Recursion Pharmaceuticals and Vir Biotechnology pages.